| Literature DB >> 35991643 |
Abstract
Introduction: Many forecasting methods are used to predict sales, such as the moving average method, naive method, exponential smoothing methods, Holt's linear method, and others. The results brought by these models are quite different. Forecast delivered by the naive method is entirely accurate for an extended period, like 3-5 years, Holt's methods are bringing accurate one-year period forecasts. The planning decisions have several levels, meaning different forecasting results. However, the authors that are testing various forecasting methods are not discussing results researched in different planning levels (retail chain and different pharmacies). The study is given to the construction of the forecasting model covering both planning levels, which later is empirically tested for the Lithuania retail case. Purpose: The development of the forecasting model for reduction of shortages in drug supply. To achieve this goal, the author revises the improvement of drug availability weekly. Research Methodology: The construction of the forecasting model is incorporating outliers' detection methods and sales by pharmacies to minimize shortage. In the forecasting model, the author uses Theil's U2 test to evaluate forecasting accuracy. Findings: During analysis, the author constructs the model application for forecasting drug sales where weekly availability is highly recommended. The results show that forecasting on individual pharmacies level using the integration of these plans approach leads to higher accuracy. Research Limitations: The research covers 3 months of sales data. Das and Chaudhury suggest for short-sales period products use 36 days' time horizon. Ayati et al. discuss short and long-term time horizons for planning sales of drugs. Kanyalkar and Adil analyzed multi-site production and suggest that the time horizon should cover the longest lead time required for delivery of raw material, which is 12 weeks, and select 3 months (i.e., 13 weeks) as short-term time period horizon. Wongsunopparat and Chaveesuk forecast drug sales for 1-month and 12-month periods and compare the results. In this study, the focus is on short-term time-horizon, which is considered as 3 months period and also represents the longest lead-time. In the future, the study could review other periods. The author has incorporated the review of eight forecasting methods into the study by leaving other forecasting methods unresearched. Future studies could also incorporate different ARIMA methods into shortage reduction case analysis. Practical Implications: Presented forecasting model could be useful for practitioners, which analyze the reduction of the shortage of prescribed drugs. There the revision of repeated purchases is recommended for national authorities, wholesalers, and pharmacies aiming to minimize shortage. Originality/Value: The analysis to reach the highest forecast accuracy and identification of a forecasting approach which responds to the fluctuation of weekly sales for the whole pharmacy chain and separate pharmacies. The study contributes to drug sales review, where most authors analyze the total volume, which is not separated by pharmacies.Entities:
Keywords: accuracy; drug; forecasting; model; planning levels; shortage
Year: 2022 PMID: 35991643 PMCID: PMC9381873 DOI: 10.3389/fmed.2022.582186
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
The summary of methods applied for drugs sales forecasting.
|
|
|
|
|---|---|---|
| Methods with no seasonality | Single exponential smoothing | ( |
| Moving average | ( | |
| Naive | ( | |
| Holt's linear | This paper | |
| Holt-Winters no trend | This paper | |
| Non-seasonal ARIMA | ( | |
| Methods with seasonality | Holt-Winters additive | ( |
| Holt-Winters multiplicative | ( | |
| Double exponential smoothing | ( | |
| Seasonal ARIMA (SARIMA) | ( | |
| Modified methods | Holt's linear with damping parameter | ( |
| Theta (Holt's linear with smoothing parameter) | ( | |
| ETS (Double exponential smoothing with unpredictable change) | ( | |
| Hybrid methods | ARHOW (ARIMA & Holt-Winters additive) | ( |
The summary of studies on hierarchical planning approach.
|
|
|
|
|---|---|---|
| Kanyalkar and Adil ( | Two | Time |
| Katayama ( | Two | Product, time |
| Mehra et al. ( | Two | Product, time |
| Moreira and Oliveira ( | Two | Product, time |
| Leong et al. ( | Three | Product, time |
| Tsubone and Sugawara ( | Three | Product |
Figure 1Grubbs test.
Figure 2Selection of appropriate forecasting methods.
Figure 3Seasonality impact check.
The values in components.
|
|
|
|
|
|---|---|---|---|
| Single exponential smoothing method | a = 0.2 | Holt-Winter‘s no trend method | a = 0.2, c = 0.05 |
| Moving average method | interval is equal to 2 | Holt-Winter‘s additive method | a = 0.2, b = 0.15, c = 0.05 |
| Naive method | interval is equal to 1 | Holt-Winter‘s multiplicative method | a = 0.2, b = 0.15, c = 0.05 |
| Holt‘s linear method | a = 0.4, b = 0.7 | Double exponential smoothing method | a = 0.2, c = 0.15 |
The results of forecasting (first approach and product without shortage).
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| 1 | 21819 | N/A | 22496 | N/A | 22496 | 21739 | 21739 | 21883 | N/A |
| 2 | 22344 | 21819 | 22496 | N/A | 22496 | 21856 | 21856 | 21867 | 21819 |
| 3 | 20675 | 21924 | 21794 | 22081 | 21725 | 22086 | 22086 | 21986 | 22344 |
| 4 | 22695 | 21674 | 20865 | 21509 | 20301 | 21818 | 21818 | 21658 | 20675 |
| 5 | 18226 | 21878 | 20581 | 21685 | 20925 | 22125 | 22125 | 21917 | 22695 |
| 6 | 19217 | 21147 | 19389 | 20460 | 18755 | 21169 | 21169 | 20994 | 18226 |
| 7 | 17944 | 20761 | 18628 | 18721 | 17979 | 20622 | 20622 | 20550 | 19217 |
| 8 | 17799 | 20198 | 17745 | 18580 | 16995 | 19822 | 19820 | 19898 | 17944 |
| 9 | 18986 | 19718 | 17010 | 17871 | 16571 | 19119 | 19115 | 19373 | 17799 |
| 10 | 24854 | 19571 | 16720 | 18392 | 17467 | 18865 | 18860 | 19276 | 18986 |
| 11 | 16402 | 20628 | 17905 | 21920 | 22421 | 20260 | 20255 | 20671 | 24854 |
| 12 | 18272 | 19783 | 17117 | 20628 | 20327 | 19177 | 19171 | 19603 | 16402 |
| 13 | 19393 | 19480 | 16896 | 17337 | 19243 | 18776 | 18769 | 19270 | 18272 |
| Forecast accuracy | |||||||||
| MAPE | 10.98 | 8.21 | 12.29 | 10.19 | 9.81 | 9.81 | 9.81 | 12.86 | |
| MSE | 6852580 | 7001301 | 9211742 | 8947946 | 6558724 | 6558831 | 6329627 | 11814118 | |
| U2 | 0.58003 | 0.59262 | 0.77972 | 0.75739 | 0.55516 | 0.55517 | 0.53577 | 1.0 | |
The results of forecasting (second approach and product without shortage).
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|
| MAPE | 10.49 | 8.03 | 11.44 | 9.50 | 9.39 | 9.39 | 9.40 | 12.04 |
| MSE | 5827558 | 5830398 | 7362487 | 7070061 | 5498635 | 5498758 | 5305605 | 9473552 |
| U2 | 0.61514 | 0.61544 | 0.77716 | 0.74629 | 0.58042 | 0.58043 | 0.56004 | 1.0 |
The results of forecasting (third approach and product without shortage).
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|
| MAPE | 10.98 | 8.21 | 12.29 | 10.19 | 9.77 | 9.81 | 9.81 | 12.86 |
| MSE | 6852580 | 7001301 | 9211742 | 8947946 | 6551488 | 6558831 | 6329627 | 11814118 |
| U2 | 0.58003 | 0.59262 | 0.77972 | 0.75739 | 0.55455 | 0.55517 | 0.53577 | 1.0 |
The results of forecasting (fourth approach and product without shortage).
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|
| MAPE | 12.37 | 7.21 | 10.53 | 8.36 | 8.70 | 8.73 | 8.65 | 9.98 |
| MSE | 7173227 | 4218869 | 5729728 | 5451635 | 4393754 | 4404285 | 4224950 | 6787283 |
| U2 | 1.05686 | 0.62158 | 0.84419 | 0.80321 | 0.64735 | 0.64890 | 0.62248 | 1.0 |
The results of forecasting (first approach and product with shortage).
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3037 | N/A | 3037 | N/A | 3037 | 3005 | 3005 | 2874 | N/A |
| 2 | 2910 | 3037 | 3037 | N/A | 3037 | 2926 | 2926 | 2914 | 3037 |
| 3 | 2751 | 3011 | 2882 | 2973 | 2825 | 2835 | 2835 | 2913 | 2910 |
| 4 | 2799 | 2959 | 2722 | 2830 | 2613 | 2726 | 2725 | 2873 | 2751 |
| 5 | 2375 | 2927 | 2606 | 2775 | 2557 | 2656 | 2656 | 2854 | 2799 |
| 6 | 2469 | 2816 | 2422 | 2587 | 2303 | 2493 | 2493 | 2734 | 2375 |
| 7 | 2530 | 2747 | 2295 | 2422 | 2234 | 2391 | 2391 | 2668 | 2469 |
| 8 | 0.0001 | 2703 | 2212 | 2499 | 2300 | 2332 | 2332 | 2633 | 2530 |
| 9 | 0.0001 | 2163 | 1573 | 1265 | 684 | 1619 | 1610 | 1975 | 0,0001 |
| 10 | 10 | 1730 | 1015 | 0 | −477 | 1038 | 1013 | 1481 | 0,0001 |
| 11 | 1794 | 1386 | 541 | 5 | −1033 | 579 | 532 | 1113 | 10 |
| 12 | 1449 | 1467 | 556 | 902 | 137 | 684 | 632 | 1283 | 1794 |
| 13 | 1846 | 1464 | 525 | 1621 | 1069 | 699 | 650 | 1325 | 1449 |
| Forecast accuracy | |||||||||
| MAPE | 1731 | 935 | 31 | 229595084 | 953 | 931 | 1349 | 21106 | |
| MSE | 1320448 | 972673 | 1057640 | 1270897 | 969960 | 987844 | 1087908 | 841361 | |
| U2 | 1.56 | 1.15 | 1.25 | 1.51 | 1.15 | 1.17 | 1.29 | 1.0 | |
Summary statistics before treatment and after treatment (product with shortage).
|
| |||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| Pharma1 | 13 | 3 | 10 | 127 | 383 | 296 | 82.99 |
| Pharma2 | 13 | 3 | 10 | 212 | 406 | 318.4 | 64,48 |
| Pharma3 | 13 | 3 | 10 | 143 | 432 | 306.1 | 93.01 |
| Pharma4 | 13 | 3 | 10 | 194 | 375 | 320.1 | 54.66 |
| Pharma5 | 13 | 3 | 10 | 167 | 384 | 286.1 | 77.71 |
| Pharma6 | 13 | 3 | 10 | 149 | 376 | 286.4 | 81.51 |
| Pharma7 | 13 | 3 | 10 | 217 | 397 | 309.4 | 59.42 |
| Pharma8 | 13 | 2 | 11 | 10 | 383 | 248.7 | 128.12 |
|
| |||||||
|
|
|
|
|
|
|
|
|
| Pharma1 | 13 | 0 | 13 | 127 | 383 | 296 | 71.87 |
| Pharma2 | 13 | 0 | 13 | 212 | 406 | 318.4 | 55.84 |
| Pharma3 | 13 | 0 | 13 | 143 | 432 | 306.1 | 80.55 |
| Pharma4 | 13 | 0 | 13 | 194 | 375 | 320.1 | 47.34 |
| Pharma5 | 13 | 0 | 13 | 167 | 384 | 286.1 | 67.30 |
| Pharma6 | 13 | 0 | 13 | 149 | 376 | 286.4 | 70.58 |
| Pharma7 | 13 | 0 | 13 | 217 | 397 | 309.4 | 51.46 |
| Pharma8 | 13 | 0 | 13 | 10 | 383 | 248.7 | 116.95 |
The results of forecasting (second approach and product with shortage).
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|
| MAPE | 15.86 | 7.11 | 9.27 | 8.00 | 6.01 | 6.02 | 11.86 | 7.06 |
| MSE | 152158 | 35305 | 65323 | 49069 | 26876 | 26934 | 100024 | 52759 |
| U2 | 2.88405 | 0.66918 | 1.23815 | 0.93006 | 0.50941 | 0.51051 | 1.89589 | 1.0 |
The results of forecasting (fourth approach and product with shortage).
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|
| MAPE | 15.86 | 6.88 | 9.27 | 8.00 | 6.01 | 6.02 | 11.86 | 7.06 |
| MSE | 152158 | 30656 | 65323 | 49069 | 26763 | 26934 | 100024 | 52759 |
| U2 | 2.88405 | 0.58107 | 1.23815 | 0.93006 | 0.50728 | 0.51051 | 1.89589 | 1.0 |
The results of Grubbs' tests by-products and accumulated sales (product with shortage).
|
|
|
|
|
|---|---|---|---|
| 24854 | 2.089 | 2.412 | yes |
The results of Grubbs' tests by pharmacies (product without shortage).
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | - | 1.901 | 2.462 | Yes |
| 2 | 1,877 | 2.147 | 2.462 | Yes |
| 3 | - | 1.833 | 2.462 | No |
| 4 | - | 1.741 | 2.462 | No |
| 5 | 3,271 | 2.076 | 2.462 | Yes |
| 6 | - | 1.756 | 2.462 | No |
| 7 | 1,249 | 2.351 | 2.462 | Yes |
| 8 | - | 1.431 | 2.462 | No |
The results of Grubbs' tests by pharmacies (product with shortage).
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | 127 | 2.364 | 2.462 | Yes |
| 2 | - | 1.905 | 2.462 | No |
| 3 | 143 | 2.007 | 2.462 | Yes |
| 4 | 194 | 2.664 | 2.462 | Yes |
| 5 | - | 1.770 | 2.462 | No |
| 6 | - | 1.946 | 2.462 | No |
| 7 | - | 1.795 | 2.462 | No |
| 8 | 10 | 2.041 | 2.462 | Yes |